CMPX

Compass Therapeutics, Inc.

1.12 USD
+0.01 (+0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Compass Therapeutics, Inc. stock is down -28.21% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trials for colorectal and ovarian cancer.